Structure Therapeutics Reports Strong Phase 2 ACCESS II Data for Oral GLP-1 Aleniglipron with 16% Weight Loss
Structure Therapeutics announced positive topline data from the Phase 2 ACCESS II trial of once-daily oral GLP-1 receptor agonist aleniglipron on March 16, 2026.
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks, described as the highest efficacy among oral GLP-1RAs and comparable to injectables.
No evidence of weight loss plateau; low AE-related discontinuation rates (2-3.4%) in OLE and body composition studies.
End-of-Phase 2 FDA meeting scheduled for Q2 2026; Phase 3 initiation on track for 2H 2026 with starting dose of 2.5 mg up to 240 mg.
CEO Raymond Stevens highlighted aleniglipron's potential as best-in-class oral GLP-1 with injectable-like efficacy.